



One Kendall Square
Building 1400W, 1st Floor
Cambridge, MA 02139 U.S.A.
T. (617) 577-7755
F. (617) 577-7756
www.semprusbio.com

FOR IMMEDIATE RELEASE

Contact: Holly P. Glass
Holly.glass@semprusbio.com
703.754.2848

SEMPRUS BIOSCIENCES AWARDED \$500,000 NATIONAL SCIENCE FOUNDATION GRANT

Cambridge, MA (September 22, 2010)—Semprus BioSciences, Corp., a biomedical company developing a proprietary vascular access product platform, today announced the company has received a \$500,000 Phase II-B Grant from the National Science Foundation (NSF). This funding will support Semprus BioSciences' product line featuring its long acting Semprus Sustain™ Performance. This unique technology is the first non-leaching single surface modification that simultaneously reduces bacterial growth and thrombus formation (blood clots) on medical devices with multi-month efficacy, according to the company.

This grant is part of the NSF's Small Business Innovation Research Program, and the third such award for Semprus BioSciences. Each year, the NSF receives more than 45,000 competitive requests for funding and makes approximately 11,500 new funding awards. The company has also recently received funding from the National Institute of Health, the U.S. Department of Energy and the U.S. Department of Defense.

"Semprus BioSciences has broken through the fundamental technical barriers of long duration blood performance (greater than 90 days), and has achieved results that will ultimately transform the medical technology industry," said David L. Lucchino, Semprus BioSciences' Chief Executive Officer. "The NSF's funding accelerates our timeline to take a giant step forward in bringing a lifesaving, life-enhancing medical device to the market."

Semprus BioSciences was founded in 2007, a spin-out from the labs of famed Massachusetts Institute of Technology researcher and entrepreneur, Robert Langer, ScD.

Semprus BioSciences' dual mission is to provide complication-free medical devices designed to preserve patients' long-term health and quality-of-life *and* to contribute to health care cost efficiencies. Public reporting and mounting pressure from hospital administration to reduce preventable and unreimbursed device-related complications have created a significant market opportunity for Semprus.

Unlike current short-duration coatings which elute agents (i.e. silver, heparin or antibiotics) that can cause toxicity or resistant bacterial strains, Semprus BioSciences' non-leaching technology doesn't require elution from the device to achieve its mechanically-repelling, anti-cell attachment effect. As a result, the technology maintains its effectiveness over extended periods of time.



One Kendall Square
Building 1400W, 1st Floor
Cambridge, MA 02139 U.S.A.
T. (617) 577-7755
F. (617) 577-7756
www.semprusbio.com

“The Phase II-B award will be instrumental in helping us achieve several key milestones in the commercialization process of Semprus Sustain™ Performance,” explained Chief Technology Officer, Dr. Christopher Loose. “We are proud to be NSF award recipients since the very inception of our company.” In 2007 and 2008, Semprus BioSciences was awarded Phase I and Phase II grants to develop its novel surface technology and optimize its performance. Semprus is also developing promising applications outside of the medical field.

#

Semprus BioSciences is a venture-backed biomedical company headquartered in Cambridge, Massachusetts. Our innovative, multi-faceted Semprus Sustain™ Performance signifies a breakthrough in medical device technology. Our current focus is to develop a vascular access catheter with the first single surface modification that simultaneously prevents bacterial and thrombus adherence over the life of the implant. This multi-dimensional Semprus Sustain™ Performance technology includes a long lasting anti-fouling surface which can be designed to deliver drugs or multiple co-immobilized agents to address a wide range of clinical problems. Visit www.semprusbio.com for additional information.